LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Verve Therapeutics Inc

Затворен

11.3 0.53

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.24

Максимум

11.31

Ключови измерители

By Trading Economics

Приходи

19M

-31M

Продажби

20M

33M

EPS

-0.35

Марж на печалбата

-94.108

Служители

274

EBITDA

19M

-35M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+34.34% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

604M

992M

Предишно отваряне

10.77

Предишно затваряне

11.3

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Verve Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.06.2025 г., 11:56 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17.06.2025 г., 14:02 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17.06.2025 г., 12:12 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17.06.2025 г., 11:01 ч. UTC

Придобивния, сливания и поглъщания

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17.06.2025 г., 10:47 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17.06.2025 г., 10:47 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17.06.2025 г., 10:46 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17.06.2025 г., 10:45 ч. UTC

Придобивния, сливания и поглъщания

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17.06.2025 г., 09:33 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Verve Therapeutics Inc Прогноза

Ценова цел

By TipRanks

34.34% нагоре

12-месечна прогноза

Среден 15.06 USD  34.34%

Висок 24 USD

Нисък 11 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Verve Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

4

Купи

6

Задържане

0

Продай

Техническа оценка

By Trading Central

4.1501 / 5.16Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.